Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

Rezultati

Naziv:	Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
Autori :	Schneeweiss, Andreas; ...; Stamatovic, Ljiljana; ...; (broj, koautora 20)
Godina:	2019
Publikacija:	JOURNAL OF CLINICAL ONCOLOGY
ISSN:	0732-183X Journal of Clinical Oncology Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 37 br. 15 str. 513-513
DOI:	10.1200/JCO.2019.37.15_suppl.513
WoS-ID:	000487345803506
URI:	https://enauka.gov.rs/handle/123456789/815546
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

1
OpenCitations

2
WEB OF SCIENCE^TM

Alt metrika

Dimensions

Unpaywall

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.